News & Media
Radius Pharmaceuticals Expands Abaloparatide Licensing Agreement with Theramex Granting Additional Commercialization Rights Including Mexico, Canada, South Africa, Israel, and Russia
Published on December 9, 2024
Radius Pharmaceuticals Announces the Appointment of Renata Sklodowska, M.D. as Senior Vice President of Medical Operations
Published on June 25, 2024
Radius Announces Presentation of Data on TYMLOS (abaloparatide) at the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases
Published on April 16, 2024
Radius Health Announces the Appointment of Bethany Sensenig as Chief Financial Officer
Published on September 26, 2023
Radius Health Announces Expansion of its Bone Health Business Through the Exclusive Licensing of U.S. Rights to BINOSTO® for Osteoporosis
Published on September 19, 2023
RADIUS ANNOUNCES ROYALTY PURCHASE AGREEMENT WITH DRI HEALTHCARE TO SELL A PORTION OF ITS ROYALTY AND COMMERCIAL MILESTONE INTEREST IN ELACESTRANT FOR UP TO $140 MILLION
Published on August 14, 2023
Radius Appoints Al Medwar as Senior Vice President of Business and Corporate Development
Published on July 26, 2023
Radius Appoints Erika Tooman as SVP / General Counsel
Published on April 5, 2023
Theramex enters into an exclusive licensing agreement with Radius Health Inc, to commercialise ELADYNOS® in the European Economic Area, the United Kingdom, Australia and Brazil
Published on March 8, 2023
Teijin Pharma to Launch Japan-market Sales of Abaloparatide Acetate for Osteoporosis
Published on January 30, 2023